Tag Archives: Department of Defense; DOD

New FY22 Young Investigator Program: Grant for Tenure Faculty

Posted on by

The Department of Defense is offering grants to applicants on a first or second full time tenure track, or tenure track equivalent, who received a Ph.D. in or after January 2014. The DOD’s Office of Naval Research is looking to attract faculty members of Higher Education in science or engineering to support research and education in the United States Navy.

MAXIMUM AWARD AMOUNT

$510,000

OPEN TO

U.S. IHEs that offer degrees in sciences, engineering, and mathematics and Non-profits whose primary focus is scientific and educational services.

PERIOD OF PERFORMANCE

3 years

APPLICATION DUE

October 29, 2021 at 11:59 p.m. ET

EXPECTED NOTIFICATION DATE

January 7, 2022

PROJECT START DATE

April 1, 2022

For more information, visit the grant page.

Department of Defense Orthotics and Prosthetics Outcomes Research Program

Posted on by

The FY20 Defense Appropriation Act provides $15 million to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology as directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 OPORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. OPORP supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service Members and Veterans with limb loss and/or limb impairment. The intent of this research is to generate clinically useful evidence that will enhance and optimize patient outcomes. Applications submitted to the FY20 OPORP must address at least one of the following Focus Areas:

  • Orthoses or Prostheses Form: Optimize patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
  • Orthoses or Prostheses Fit: Optimize patient outcomes related to human-device interface through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
  • Orthoses or Prostheses Function: Optimize patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

Clinical Research Award – Letter of Intent due June 10, 2020

Independent investigators at all academic levels (or equivalent):

  • Supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service Members, Veterans, and other individuals with limb loss and/or limb impairment.
  • Supported research is intended to generate clinically useful evidence with potential to enhance and optimize patient outcomes.
  • Multidisciplinary collaboration among academics, industry, patient advocacy, the military Services, the Department of Veterans Affairs (VA), and/or other Federal Government agencies is highly encouraged.
  • Applications submitted to the FY20 OPORP CRA must address one or more of the FY20 OPORP Focus Areas.
  • Preclinical studies using animals are not allowed.
  • Clinical trials are not allowed.
  • The FY20 CRA offers two funding levels:
    • Funding Level 1: Maximum funding of $350,000 for total costs (direct plus indirect costs). Maximum period of performance is 2 years.
    • Funding Level 2: Maximum funding of $2,000,000 for total costs (direct plus indirect costs). Maximum period of performance is 4 years.

Clinical Trial Award – Letter of Intent due June 10, 2020

Independent investigators at all academic levels (or equivalent:

  • Supports implementation of clinical trials with the potential to have a significant impact on improving the health and well-being of Service Members, Veterans, and other individuals living with limb loss and/or limb impairment.
  • Supports clinical trials that evaluate orthoses and/or prostheses using patient-centric outcomes for the purpose of generating clinically useful evidence to enhance and optimize patient outcomes.
  • Multidisciplinary collaborations among academia, industry, patient advocacy, the Military Services, VA, and/or other Federal Government agencies is highly encouraged.
  • Applications submitted to the FY20 OPORP CTA must address one or more of the FY20 OPORP Focus Areas.
  • Preclinical research is not allowed.
  • The FY20 CTA offers two funding levels:
  • Funding Level 1
    • Funding Level 1 supports pilot clinical trials which are exploratory and involve limited human exposure with the potential to make significant advancement toward clinical translation. Preliminary data are allowed but not required. Maximum funding of $350,000 for total costs (direct plus indirect costs). Maximum period of performance is 2 years
    • Funding Level 2 supports clinical trials with the potential to make significant advancement toward clinical translation. Preliminary data relevant to the proposed clinical trial are required. Maximum funding of $4,000,000 for total costs (direct plus indirect costs). Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website.


Air Force Fiscal Year 2021 Young Investigator Research Program (YIP)

Posted on by

The Fiscal Year 2021 Air Force Young Investigator Research Program (YIP) intends to support early in career scientists and engineers who have received PhD or equivalent degrees by April 1, 2013 or later showing exceptional ability and promise for conducting basic research. The program objective is to foster creative basic research in science and engineering; enhance early career development of outstanding young investigators; and increase opportunities for the young investigator to recognize the Air Force mission and related challenges in science and engineering.

Individual awards are made to US institutions of higher education, industrial laboratories, or non-profit research organizations where the principal investigator (PI) is employed on a full-time basis and holds a regular position. YIP PIs must be a US citizen, national, or permanent resident. Researchers working at a Federally Funded Research and Development Center or DoD Laboratory are not eligible for this competition.

Most YIP awards are funded up to $150,000 per year for three years, for a total of $450,000. Each three year budget must not exceed $150,000; regardless if the total budget is $450,000. Exceptional proposals will be considered individually for higher funding levels and/or longer duration. More information can be found by clicking on the Learn More button below.

DoD FY21 Defense University Research Instrumentation Program (DURIP)

Posted on by

The Department of Defense (DoD announces the Fiscal Year 2021 Defense University Research Instrumentation Program (DURIP).

DURIP is designed to improve the capabilities of accredited United States (US) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding. We refer to eligible institutions of higher education as universities in the rest of this announcement.

DURIP is part of the University Research Initiative (URI).

This program will be supplemented by additional funding provided by the Defense Established Program to Stimulate Competitive Research (DEPSCoR). Additional awards may be made to principal investigators in DEPSCoR eligible states as defined in 10 U.S.C. 2358, as amended by Pub. L. 115 91, div. A, title II, sec. 219.

IMPORTANT NOTE: Applicants should be alert for any amendments that may modify the announcement. Amendments to the original funding opportunity announcement (FOA) will be posted to the Grants.gov Webpage.

The DURIP Announcement has been amended. Amendment 2 corrects section D.5.f. on page 21 to reflect that Bibliography and References Cited are included in the page count. This amendment supersedes previous versions of this FOA. Click on the box below and navigate to the “Related Documents” tab for the full program announcement.

Department of Defense Peer Reviewed Orthopaedic Research Program

Posted on by

The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) to support innovative, high-impact, clinically-relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 PRORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY20 PRORP must address one or more of the following FY20 Focus Areas:

  • Compartment Syndrome: Novel treatment strategies to improve current diagnoses for compartment syndrome. Alternatives to intracompartmental pressure measurements are encouraged.
  • Limb Stabilization and Protection: Development and/or clinical assessment of rapid limb stabilization and novel wound protectants for severely wounded limbs to enable transport at the point of need.
  • Orthotic Devices: Refinement of high-performance novel orthotic devices designed to enhance whole person performance and decrease pain in patients with limb salvage and impairment.
  • Osseointegration: Identification of best practices to address infection, rejection, and/or failure of percutaneous osseointegrated prosthetic limbs. 
  • Retention Strategies: Development, optimization, and/or validation of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty for common combat-related musculoskeletal injuries.  Biomarker studies are excluded.  The current standard of care must be noted.  The rehabilitation strategy and the standard of care must be specified, as applicable.
    • Point of Injury: Battlefield-feasible strategies that can be utilized at or near the point of injury to allow an injured Service member to remain on duty and stay on mission without the need for immediate evacuation
    • Point of Duty: Strategies that can be utilized along the continuum of care to allow an injured Service member to return to duty without separation from Service.
  • Tissue Regeneration Therapeutics: Development of advanced tissue regeneration therapeutics in nerve, muscle (to include volumetric muscle loss), and/or composite tissue for the restoration of traumatically injured extremities.  Isolated bone or cartilage tissue engineering studies are excluded.
  • Translation of Early Findings: Translation of early research findings in the orthopaedic surgical care topic areas listed below to move the research toward clinical trials and clinical practice.
    • Soft Tissue Trauma: Strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments for anterior cruciate ligament (ACL) or shoulder instability only, to optimize return to duty, work, or reintegration
    • Fracture-Related Infection: Strategies to decrease the burden of fracture-related infections (may include prevention, early detection, or improved eradication).  Alternatives to systemic and/or local antibiotic delivery are encouraged. 

https://cdmrp.army.mil/funding/prorp

Applied Research Award – Preproposal due May 27, 2020. Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with musculo-skeletal injuries sustained during combat or combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work.
  • Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
  • Clinical research and clinical trials are not allowed under this award mechanism.
  • Applications must address one of the following FY20 PRORP Focus Areas:
    • Limb Stabilization and Protection
    • Retention Strategies
      • Point of Injury
      • Return to Duty
  • Osseointegration

Maximum funding of $725,000 for total costs (includes direct and indirect costs). Maximum period of performance is 3 years.

Clinical Trial Award – Preproposal due May 27, 2020.Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.
  • Funding must support a clinical trial and may not be used for preclinical research studies.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
  • Applications must address one the following FY20 PRORP Focus Areas:
    • Limb Stabilization and Protection
    • Retention Strategies
      • Point of Injury
      • Return to Duty
    • Translation of Early Findings
      • Soft Tissue Trauma
      • Fracture-Related Infection

Funding Level 1:Maximum funding of $2.25M for total costs. (includes direct and indirect costs). Maximum period of performance is 4 years.

Funding Level 2 (Translation of Early Findings – Soft Tissue Trauma Focus Area with Rehabilitation Option): Maximum funding of $2.75M for total costs (includes direct and indirect costs). Maximum period of performance is 4 years.

Clinical Translational Research Award – Preproposal is due May 27, 2020. Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale, randomized, controlled clinical trial.
  • Funding must support clinical research studies involving humans.
  • Preliminary or published data relevant to the proposed research project are required.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 12 months of the award date.
  • Applications must address one of the following FY19 PRORP CTRA Focus Areas:
    • Retention Strategies
      • Point of Injury
      • Return to Duty
    • Tissue Regeneration Therapeutics
    • Compartment Syndrome
    • Osseointegration
    • Orthotic Devices

Maximum funding of $1.5M for total costs (including direct and indirect costs). Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website.